Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cemiplimab in HIV-1 on Suppressive cART
NCT03787095Phase 2Terminated
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Aug 2019
- Primary completion
- Aug 2020
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of cemiplimab in human immunodeficiency virus infection (HIV), sponsored by National Institute of Allergy and Infectious Diseases. Started Aug 2019; status: terminated.
02
Drugs
cemiplimab
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT03787095.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03787095.